Paclitaxel liposome artery infusion plus systemic therapy for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of a targeted chemotherapy infusion into the liver artery with other systemic treatments for people with advanced liver cancer that has progressed after initial immunotherapy. The goal is to see if this approach can improve outcomes for patients whose cancer has not responded to first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer (hepatocellular carcinoma) that has gotten worse after prior treatment with a PD-1 or PD-L1 immunotherapy drug.
- You have at least one measurable tumor in the liver that can be treated with an artery infusion.
- Your liver function is stable (Child-Pugh score 7 or lower) and your overall health is good (ECOG score 0 or 1).
- You have not had liver surgery or local treatment in the past 4 weeks, and have not taken the targeted therapy lenvatinib before.
- You are willing to use reliable birth control during the trial and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial compares two ways to deliver chemotherapy into the liver—TACE (a targeted injection that blocks blood flow) and HAIC (a continuous infusion through a small tube)—along with an immunotherapy drug (PD-1 inhibitor) and a targeted therapy pill (lenvatinib). It's for people with liver cancer that cannot be removed by surgery.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.